The hexosamine biosynthetic pathway and glucose-induced down regulation of glucose transport in L6 myotubes.
Based on experiments in cultured adipocytes, it has been proposed that glucose-induced down regulation of glucose transport is mediated by the conversion of fructose-6-phosphate to glucosamine-6-phosphate via the first and rate-determining enzyme of the hexosamine biosynthetic pathway, glutamine: fructose-6-phosphate amidotransferase (glutamine hexosephosphate aminotransferase). Evidence for this assertion was: (a) L-glutamine, the provider group for the aminotransferase was essential; (b) two inhibitors of glutamine hexosephosphate aminotransferase, 6-diazo-5-oxonorleucine (L form) and azaserine, blocked glucose-induced down regulation of glucose transport; (c) azaserine inhibited the activity of the aminotransferase, (d) glucosamine, which enters the hexosamine pathway distal to this enzyme was 40-times more potent than glucose; and (e) azaserine was unable to block the effect of glucosamine. Since muscle is quantitatively much more important than adipose tissue for whole body glucose utilization, we sought to determine if the hexosamine pathway was involved in glucose-induced down regulation of glucose transport in L6 myotubes. Glucose was effective, both in the presence and absence of glutamine in the incubation media. Glucosamine was also effective but was as equipotent as glucose. Small amounts of glutamine hexosephosphate aminotransferase were present in the L6 myotubes and although the leucine derivative (20 microM) inhibited the enzyme, it did not impair glucose-induced down regulation of glucose transport. Total GLUT-1 levels were similar when the cells were incubated in the absence or presence of 5 mM glucose or glucosamine although glucosamine was associated with a marked increase in a lower molecular weight band. These results do not suggest that the hexosamine biosynthetic pathway is involved in glucose-induced down regulation of glucose transport in L6 myotubes. Thus, this phenomenon is regulated differently in muscle and fat.
Davidson
M B
MB
Cedars-Sinai Research Institute, Department of Medicine, Cedars-Sinai Medical Center-UCLA 90048.
Hunt
K
K
Fernandez-Mejia
C
C
D000818:Animals; D001377:Azaserine / Q000494:pharmacology; D001692:Biological Transport; D002460:Cell Line; D003847:Deoxyglucose / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology*; D051272:Glucose Transporter Type 1; D005945:Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) / Q000037:antagonists & inhibitors; D006595:Hexosamines / Q000096:biosynthesis*; D009004:Monosaccharide Transport Proteins / Q000032:analysis; D009132:Muscles / Q000378:metabolism*; D051381:Rats
D051272:Glucose Transporter Type 1; D006595:Hexosamines; D009004:Monosaccharide Transport Proteins; C495679:Slc2a1 protein, rat; D001377:Azaserine; D003847:Deoxyglucose; D005945:Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing); D005947:Glucose